Back

Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: What’s new on lipids and diabetes in acute coronary syndrome Thrombosis, Platelets, and Coagulation ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Efthymios Ziogos

The Johns Hopkins University School of Medicine, Baltimore (United States of America)

5 More presentations in this session

Presentation thumbnail
Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome
Professor P. Steg (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Quality matters: low-density lipoprotein electronegativity but not quantity determines mortality risk in acute coronary syndromes
Doctor S. Kraler (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Glycated haemoglobin and the association with long-term survival among patients evaluated for stable angina - a prospective Norwegian cohort
Doctor G. Svingen (Bergen, NO)
Abstract Slides Video
Presentation thumbnail
Cardioprotective effect of empagliflozin in acute myocardial infarction: the role of ketone bodies availability.
Professor J. Badimon (New York City, US)
Abstract Slides Video
Presentation thumbnail
Impact of chronic GLP-1 receptor agonist and SGLT-2 inhibitor therapy on in-hospital outcomes of patients with diabetes mellitus hospitalized with acute myocardial infarction.
Doctor F. Trombara (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
What’s new on lipids and diabetes in acute coronary syndrome

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial
thumbnail
Congress Presentation
Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis
thumbnail
Congress Presentation
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources